OBJECTIVE: Invasive aspergillosis is associated with a poor prognosis, especially in critically ill patients with cerebral involvement. We present two cases of cerebral invasive aspergillosis successfully treated in the intensive care unit with combination antifungal therapies and without surgery. CASE PRESENTATION: The first patient was a 49-year-old man with rheumatoid arthritis who received corticosteroid and cyclophosphamide treatment and developed pulmonary and cerebral invasive aspergillosis. After failure of voriconazole the patient had a successful outcome with voriconazole and liposomal amphotericin B therapy. The patient returned home after an 8-month hospital stay. The second patient was a 54-year-old woman with pulmonary neoplasia and corticosteroid treatment who developed pulmonary and cerebral invasive aspergillosis. After failure of voriconazole and liposomal amphotericin B therapy the patient had a favorable outcome with liposomal amphotericin B and caspofungin therapy. The patient died 10 months after initial diagnosis of cardiac tamponade unrelated to fungal infection. DISCUSSIONS: These cases illustrate the improving prognosis of invasive aspergillosis due to the availability of new treatments, especially in cases of cerebral involvement. It also demonstrates that the outcome of critically ill patients requiring mechanical ventilation for invasive aspergillosis can be favorable. The treatment of patients with invasive cerebral aspergillosis in the intensive care setting should be encouraged.
OBJECTIVE:Invasive aspergillosis is associated with a poor prognosis, especially in critically ill patients with cerebral involvement. We present two cases of cerebral invasive aspergillosis successfully treated in the intensive care unit with combination antifungal therapies and without surgery. CASE PRESENTATION: The first patient was a 49-year-old man with rheumatoid arthritis who received corticosteroid and cyclophosphamide treatment and developed pulmonary and cerebral invasive aspergillosis. After failure of voriconazole the patient had a successful outcome with voriconazole and liposomal amphotericin B therapy. The patient returned home after an 8-month hospital stay. The second patient was a 54-year-old woman with pulmonary neoplasia and corticosteroid treatment who developed pulmonary and cerebral invasive aspergillosis. After failure of voriconazole and liposomal amphotericin B therapy the patient had a favorable outcome with liposomal amphotericin B and caspofungin therapy. The patient died 10 months after initial diagnosis of cardiac tamponade unrelated to fungal infection. DISCUSSIONS: These cases illustrate the improving prognosis of invasive aspergillosis due to the availability of new treatments, especially in cases of cerebral involvement. It also demonstrates that the outcome of critically ill patients requiring mechanical ventilation for invasive aspergillosis can be favorable. The treatment of patients with invasive cerebral aspergillosis in the intensive care setting should be encouraged.
Authors: Johan Maertens; Issam Raad; George Petrikkos; Marc Boogaerts; Dominik Selleslag; Finn B Petersen; Carole A Sable; Nicholas A Kartsonis; Angela Ngai; Arlene Taylor; Thomas F Patterson; David W Denning; Thomas J Walsh Journal: Clin Infect Dis Date: 2004-11-09 Impact factor: 9.079
Authors: K Vandewoude; D Vogelaers; J Decruyenaere; P Jaqmin; K De Beule; A Van Peer; R Woestenborghs; K Groen; F Colardyn Journal: Antimicrob Agents Chemother Date: 1997-12 Impact factor: 5.191
Authors: A H Groll; N Giri; V Petraitis; R Petraitiene; M Candelario; J S Bacher; S C Piscitelli; T J Walsh Journal: J Infect Dis Date: 2000-07-06 Impact factor: 5.226
Authors: G Damaj; V Ivanov; B Le Brigand; E D'incan; M F Doglio; K Bilger; C Faucher; N Vey; J A Gastaut Journal: Ann Hematol Date: 2003-12-10 Impact factor: 3.673
Authors: V de Lastours; A Lefort; M Zappa; V Dufour; N Belmatoug; B Fantin Journal: Eur J Clin Microbiol Infect Dis Date: 2003-05-10 Impact factor: 3.267